KUMAR AMIT purchased $16K of ANIX

KUMAR AMIT (Chief Executive Officer) purchased 5,000 shares of Anixa Biosciences Inc (ANIX) at $3.17 on 2026-10-30.

Original reporting
SEC EDGAR · KUMAR AMIT
Published Nov 2, 2026, 1:54 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 2, 2026, 2:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ANIX
Bullish
medium confidence
Mentioned
$ANIX
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ANIXBullishLow
01

Why it matters

The filing reveals a modest CEO purchase, which may be interpreted as a confidence signal but is unlikely to drive significant price movement.

02

Market read

Small insider purchase; low trading relevance.

03

What to watch

Potential upcoming clinical data or financing events could give the purchase more meaning.

Relevance 4/10Novelty 4/10Timing: filing date 2026-11-02

Background

Form 4 filings disclose insider transactions; they are primary sources for insider activity.

Company-level read

Ticker impact

$ANIXBullishMedium confidence
Context

CEO Kumar Amit bought 5,000 shares at $3.17, increasing his stake to 685,000 shares.

Expected impact

likely slight upward pressure as market prices in insider confidence

Evidence & confidence

The purchase is small relative to market cap but comes from the CEO, suggesting a positive view of the company.

Market effects

Minimal impact on biotech sector; insider activity is routine.

None

None

Counterpoint

The purchase is too small to move the stock; investors may ignore it.

Key entities

  • Anixa Biosciences Inc

    Biotech firm listed on NASDAQ under ticker ANIX.

  • Kumar Amit

    Chief Executive Officer of Anixa Biosciences.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ANIXMedAI 8/10

Anixa ovarian cancer trial to be presented at ESMO congress

Anixa Biosciences (NASDAQ:ANIX) will present Phase 1 trial results for its ovarian cancer treatment at the ESMO congress. The trial, led by Dr. Robert Wenham, evaluates the safety and efficacy of liraltagene autoleucel, a CAR-T therapy. The company reported no dose-limiting toxicities, stable disease in one patient, and over one-year survival in four patients. Anixa plans to advance to a sixth cohort with a 1,000-fold dose increase.

$ANIXMedAI 8/10

Anixa Biosciences Announces Presentation of Ovarian Cancer CAR-T Clinical Trial at ESMO Immuno-Oncology & Advanced Therapies Congress 2026

Anixa Biosciences (NASDAQ: ANIX) announced that Dr. Robert Wenham will present Phase 1 trial results of its CAR-T therapy for ovarian cancer at the ESMO Congress in December 2026. The trial, conducted at Moffitt Cancer Center, has completed its fifth cohort with no dose-limiting toxicities and encouraging preliminary results. The company plans to advance to a sixth cohort with a higher dose.

$ANIXMedAI 8/10

Four patients have survived over a year after treatment, one beyond two years. Anixa's trial will be presented Dec. 14.

Anixa Biosciences reported positive interim results from its Phase 1 trial of lira-cel, a CAR-T therapy for ovarian cancer. Four patients survived over a year, one beyond two years. The company plans to advance to a sixth cohort with a 1,000-fold dose increase. Results will be presented at the ESMO Immuno-Oncology & Advanced Therapies Congress on Dec. 14.

$ANIXLowAI 8/10

Anixa completes fifth cohort dosing in ovarian cancer trial

Anixa Biosciences (NASDAQ:ANIX) completed dosing the fifth cohort in its Phase 1 trial for ovarian cancer, with no dose-limiting toxicities observed. The fifth cohort received the highest dose yet, and one patient showed stable disease 90 days post-treatment. The sixth cohort will evaluate an even higher dose. The trial, conducted at Moffitt Cancer Center, aims to assess safety, tolerability, and preliminary efficacy.

$ANIXMedAI 8/10

Four ovarian cancer patients lived over a year after Anixa's experimental treatment.

Anixa Biosciences' experimental ovarian cancer treatment, lira-cel, showed promising results in a Phase 1 trial, with four patients surviving over a year. Dr. Jose Conejo-Garcia, who invented the technology, will present findings at the 2026 Ovarian Cancer Midwest Focus Conference. The trial, conducted with Moffitt Cancer Center, has not reported dose-limiting toxicities, and one patient has survived beyond two years.